HK219596A - Contrast media - Google Patents

Contrast media

Info

Publication number
HK219596A
HK219596A HK219596A HK219596A HK219596A HK 219596 A HK219596 A HK 219596A HK 219596 A HK219596 A HK 219596A HK 219596 A HK219596 A HK 219596A HK 219596 A HK219596 A HK 219596A
Authority
HK
Hong Kong
Prior art keywords
multinuclear
atom
complexes
medium
complex
Prior art date
Application number
HK219596A
Other languages
German (de)
English (en)
Inventor
Berg Arne
Almen Torsten
Dieter Krautwurst Klaus
Kim Sook-Hui
Rongved Pal
Klaveness Jo
Dugstad Harald
Original Assignee
Nycomed Imaging As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As
Publication of HK219596A publication Critical patent/HK219596A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
    • C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Liquid Crystal (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Devices For Indicating Variable Information By Combining Individual Elements (AREA)
  • Steroid Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Electric Propulsion And Braking For Vehicles (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Lubricants (AREA)

Claims (9)

  1. Procédé de préparation d'une substance de contraste radiologique comprenant l'étape consistant à associer au moins un véhicule ou excipient pharmaceutique avec un complexe multinucléaire physiologiquement tolérable de formule         (W3BuAv)xLw     (X) (dans laquelle W3BuAv est une entité multinucléaire ; chaque atome de tungtène est lié par covalence à au moins un atome B ; chacun des B qui peuvent être identiques ou différents est un atome de pontage lié par covalence à au moins deux atomes de tungstène ; chacun des A qui peuvent être identiques ou différents est un atome ne créant pas de pont, lié par covalence à un atome de tungstène ; chacun des L qui peuvent être identiques ou différents, est un ligand lié par coordination à au moins un atome de tungstène ; u est un entier positif de valeur 2 ou plus ; x et w sont des entiers positifs ; et v est zéro ou un entier positif) ou un sel physiologiquement tolérable de celui-ci.
  2. Procédé selon la revendication 1 où chaque A et B de l'entité multinucléaire est O, S, Se, Te ou un atome d'azote ou de phosphore protoné ou substitué.
  3. Procédé selon la revendication 2 où l'entité multinucléaire comprend une unité de formule W3(µ3B)(µ2B)3 où chaque B est O, S, Se, Te ou un atome d'azote ou de phosphore protoné ou substitué.
  4. Procédé selon l'une quelconque des revendications 1 à 3 où ledit complexe multinucléaire est un complexe avec un chélatant polyamine.
  5. Procédé selon la revendication 4 où ledit chélatant est un acide aminopolycarboxylique ou un ester ou amide de celui-ci ou est une polyamine polyacylée macrocyclique.
  6. Procédé de formation d'une image radiologique de l'organisme de l'homme ou d'un animal autre que l'homme qui comprend l'administration audit organisme d'un complexe multinucléaire physiologiquement tolérable tel que défini dans la revendication 1 et la formation d'une image radiologique d'au moins une partie dudit organisme.
HK219596A 1990-03-28 1996-12-24 Contrast media HK219596A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909006977A GB9006977D0 (en) 1990-03-28 1990-03-28 Compositions
PCT/EP1991/000587 WO1991014460A1 (fr) 1990-03-28 1991-03-27 Substances de contraste

Publications (1)

Publication Number Publication Date
HK219596A true HK219596A (en) 1997-01-03

Family

ID=10673438

Family Applications (1)

Application Number Title Priority Date Filing Date
HK219596A HK219596A (en) 1990-03-28 1996-12-24 Contrast media

Country Status (18)

Country Link
US (2) US5458869A (fr)
EP (2) EP0521977B1 (fr)
JP (1) JPH06507147A (fr)
AT (1) ATE142508T1 (fr)
AU (1) AU645796B2 (fr)
CA (1) CA2079212A1 (fr)
DE (1) DE69122092T2 (fr)
DK (1) DK0521977T3 (fr)
ES (1) ES2091323T3 (fr)
FI (1) FI924297A7 (fr)
GB (1) GB9006977D0 (fr)
HK (1) HK219596A (fr)
HU (2) HUT69168A (fr)
LT (1) LT3535B (fr)
LV (1) LV10056B (fr)
NO (1) NO923739L (fr)
SG (1) SG43931A1 (fr)
WO (1) WO1991014460A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017215A1 (fr) 1990-03-28 1992-10-15 Nycomed Salutar, Inc. Milieux de contraste
GB9006977D0 (en) * 1990-03-28 1990-05-23 Nycomed As Compositions
DE69230400T2 (de) * 1991-03-27 2000-08-03 Nycomed Salutar Inc., Wayne Kontrastmittel
US5330742A (en) * 1991-08-05 1994-07-19 Mallinckrodt Medical, Inc. Methods and compositions for magnetic resonance imaging
AU670029B2 (en) * 1991-08-05 1996-07-04 Mallinckrodt Medical, Inc. Heavy metal clusters for use as imaging agents
US5364953A (en) * 1992-11-05 1994-11-15 Mallinckrodt Medical, Inc. High relaxivity, paramagnetic, metal clusters for magnetic resonance imaging
GB9407812D0 (en) * 1994-04-20 1994-06-15 Nycomed Salutar Inc Compounds
GB9420390D0 (en) * 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
US5717121A (en) * 1995-06-07 1998-02-10 Nycomed Salutar, Inc. Preparation and use of contrast agents
GB9601340D0 (en) * 1996-01-23 1996-03-27 Nycomed Salutar Inc Contrast media
JP3839059B2 (ja) * 1996-02-14 2006-11-01 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴイ Ｘ線フィルタを有するｘ線検査装置
US5804161A (en) * 1996-05-14 1998-09-08 Nycomed Salutar Inc. Contrast agents
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
EP1140204A2 (fr) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Medicaments antagonistes du recepteur de la vitronectine
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2349333A1 (fr) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Medicaments antagonistes du recepteur de la vitronectine
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6596259B1 (en) 1998-12-22 2003-07-22 University Of Puerto Rico Metal based cubane structure contained in an octanuclear complex stable over several oxidation states and a method of producing the same
US7807137B1 (en) 1998-12-22 2010-10-05 University Of Puerto Rico Iron-based contrast agent
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6878363B2 (en) 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
CN1386118A (zh) 2000-06-01 2002-12-18 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物
CA2427911A1 (fr) 2000-11-03 2002-05-10 Bristol Myers Squibb Company Double imagerie isotopique simultanee d'une perfusion et d'une inflammation cardiaque
US7928278B2 (en) * 2001-06-12 2011-04-19 University Of Florida Research Foundation, Inc. Method and apparatus for producing near-infrared radiation
US6838074B2 (en) 2001-08-08 2005-01-04 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US7138104B2 (en) 2001-08-08 2006-11-21 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
US7485283B2 (en) 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
JP4322781B2 (ja) * 2004-11-08 2009-09-02 富士フイルム株式会社 撮像装置
WO2007005491A1 (fr) * 2005-06-30 2007-01-11 Bristol-Myers Squibb Pharma Company Conjugues d'hydrazide en tant qu'agents d'imagerie
US7824659B2 (en) 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
US20070098640A1 (en) * 2005-11-02 2007-05-03 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography
US9149545B2 (en) * 2005-11-02 2015-10-06 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography and methods for making same
EP1991577A2 (fr) 2006-01-31 2008-11-19 Parkinson, John F. Modulation de l'activite mdl-1 pour le traitement de maladies inflammatoires
WO2009108376A2 (fr) 2008-02-29 2009-09-03 Lantheus Medical Imaging, Inc. Agents de contraste utilisés dans des applications notamment l’imagerie de perfusion
EP2296550B1 (fr) * 2008-07-07 2018-03-28 Koninklijke Philips N.V. Imagerie de bord k
KR20160030589A (ko) 2009-04-15 2016-03-18 랜티우스 메디컬 이메징, 인크. 아스코르브산을 사용한 방사성 약제 조성물의 안정화
WO2011035140A1 (fr) 2009-09-18 2011-03-24 Paka Pulmonary Pharmaceuticals, Inc. Procédés et compositions pour la délivrance de moitiés de contraste aux poumons
DK3323810T3 (da) 2010-02-08 2022-03-28 Lantheus Medical Imaging Inc Automatiseret reaktionssystem, kassette og indretning til syntese af billeddannelsesmidler
EP2540321A1 (fr) 2011-06-30 2013-01-02 Bayer Intellectual Property GmbH Groupes W302 bis-tridentate pour imagerie à rayons X
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
EP2733148A1 (fr) 2012-11-15 2014-05-21 Bayer Pharma Aktiengesellschaft Complexes de tungstène avec ligands di-dentés
JP6549554B2 (ja) 2013-03-15 2019-07-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア コレステロール流出を刺激する、減少した毒性を有するペプチド

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US468759A (en) 1892-02-09 Gabeiel a
US3860611A (en) * 1972-01-19 1975-01-14 Du Pont Macrocyclic polyether polyols and condensation polymers derived therefrom
US3763188A (en) * 1972-01-19 1973-10-02 Du Pont Spiro(1,1-polyethylenedi(oxymethyl))-3-oxetanes
US3952015A (en) * 1973-11-12 1976-04-20 Carl George Krespan Macrocyclic compounds having oxa and aza linkages in the ring and containing spirooxetane groups
US4079124A (en) * 1976-04-21 1978-03-14 Medi-Physics, Inc. Method of preparing X-ray contrast media containing ores of hafnium, tantalum and tungsten
US4176173A (en) * 1977-07-18 1979-11-27 Medi-Physics, Inc. Radiographic compositions
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4652519A (en) 1983-02-03 1987-03-24 Yeda Research And Development Company Limited Bifunctional chelating agents and process for their production
US4826673A (en) 1985-01-09 1989-05-02 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
CA1282069C (fr) 1985-09-12 1991-03-26 Damon L. Meyer Complexes d'anticorps comprenant des agents therapeutiques ou de diagnostic modifies par des haptenes
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
JP2833766B2 (ja) 1987-07-16 1998-12-09 ニユコメド・アクシエセルカペト アミノポリカルボン酸およびその誘導体
FR2630547A1 (fr) * 1988-04-22 1989-10-27 Centre Nat Rech Scient Marquage froid de molecules de nature peptidique ou proteique
US5260050A (en) * 1988-09-29 1993-11-09 Ranney David F Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes
EP0361960A3 (fr) * 1988-09-29 1992-01-02 RANNEY, David F. Procédé et compositions pour la production d'images par résonance magnétique
GB9006977D0 (en) * 1990-03-28 1990-05-23 Nycomed As Compositions
US5186923A (en) * 1990-10-10 1993-02-16 Brigham And Womens Hospital Enhancement of cellular accumulation of lipophilic cationic organometallic compounds by reduction of intramembrane potential
AU670029B2 (en) * 1991-08-05 1996-07-04 Mallinckrodt Medical, Inc. Heavy metal clusters for use as imaging agents

Also Published As

Publication number Publication date
AU645796B2 (en) 1994-01-27
CA2079212A1 (fr) 1991-09-29
DK0521977T3 (da) 1996-09-30
LT3535B (en) 1995-11-27
LV10056A (lv) 1994-05-10
JPH06507147A (ja) 1994-08-11
FI924297A0 (fi) 1992-09-25
NO923739L (no) 1992-11-06
HU9203086D0 (en) 1992-12-28
ATE142508T1 (de) 1996-09-15
US5458869A (en) 1995-10-17
GB9006977D0 (en) 1990-05-23
NO923739D0 (no) 1992-09-25
EP0521977A1 (fr) 1993-01-13
WO1991014460A1 (fr) 1991-10-03
DE69122092T2 (de) 1997-03-06
ES2091323T3 (es) 1996-11-01
FI924297L (fi) 1992-09-25
FI924297A7 (fi) 1992-09-25
LV10056B (en) 1995-02-20
LTIP609A (en) 1994-12-27
AU7557891A (en) 1991-10-21
EP0645146A1 (fr) 1995-03-29
US5614168A (en) 1997-03-25
EP0521977B1 (fr) 1996-09-11
DE69122092D1 (de) 1996-10-17
SG43931A1 (en) 1997-11-14
HUT69168A (en) 1995-08-28

Similar Documents

Publication Publication Date Title
EP0521977B1 (fr) Substances de contraste
US5804161A (en) Contrast agents
EP0577675B1 (fr) Milieux de contraste
WO1992017215A1 (fr) Milieux de contraste
US7385041B2 (en) Dual functioning excipient for metal chelate contrast agents
JPH04502619A (ja) 複素環式キレート化剤
CA2039399C (fr) Excipient a double fonction pour les agents de contraste a base de chelate metallique
NZ236267A (en) 10-(2'-hydroxy-3'-polyoxaalkyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane
CA1230342A (fr) Tc99m-phenida, agent radioscintigraphique pour le diagnostic des affections hepatobiliaires
HK1006364A (en) Contrast media
US5717121A (en) Preparation and use of contrast agents
EP0876161B1 (fr) Substances de contraste
MXPA98009385A (es) Agentes de contraste

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)